Analyst Ratings for Rallybio
Portfolio Pulse from Benzinga Insights
In the last quarter, Rallybio (NASDAQ:RLYB) received 5 bullish to somewhat bullish ratings from analysts, with no indifferent or bearish ratings. The average 12-month price target for the company is $17.2, representing a 20.0% decrease from the previous average price target of $21.50.
August 10, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Rallybio received 5 bullish ratings from analysts in the last quarter. However, the average 12-month price target has decreased by 20.0% to $17.2.
The bullish ratings indicate a positive outlook for Rallybio. However, the decrease in the average price target suggests that analysts expect the stock price to decrease in the future. This could lead to a neutral impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100